MII PR MTB Systemtherapie Medication Statement - MII IG Kerndatensatz-Modul Molekulares Tumorboard v2027.0.0-ballot.1

MII IG Kerndatensatz-Modul Molekulares Tumorboard
2027.0.0-ballot.1 - Germany

This page is part of the MII Implementation Guide Molecular Tumor Board (v2027.0.0-ballot.1: Release) based on FHIR (HL7® FHIR® Standard) R4. This is the current published version. For a full list of available versions, see the Directory of published versions

Resource Profile: MII PR MTB Systemtherapie Medication Statement - Examples

Active as of 2026-09-15

Examples for the mii-pr-mtb-systemtherapie-medication-statement Profile.

24.06.2023 Z1 Mirvetuximab soravtansine 6mg/kg KG, Wdh d22

16.07.2023 Z2 Mirvetuximab soravtansine 6mg/kg KG, Wdh d22

07.08.2023 Z3 Mirvetuximab soravtansine 6mg/kg KG, Wdh d22

29.08.2023 Z4 Mirvetuximab soravtansine 6mg/kg KG, Wdh d22

20.09.2023 Z5 Mirvetuximab soravtansine 6mg/kg KG, Wdh d22

12.10.2023 Z6 Mirvetuximab soravtansine 6mg/kg KG, Wdh d22

24.06.2023 Z1 Mirvetuximab soravtansine 6mg/kg KG, Wdh d22

IG © 2024+ Medizininformatik-Initiative. Package de.medizininformatikinitiative.kerndatensatz.mtb#2027.0.0-ballot.1 based on FHIR 4.0.1. Generated 2026-09-15
Links: Table of Contents | QA Report | netzwerk-universitaetsmedizin.de | medizininformatik-initiative.de | Legal notice
HL7®, FHIR® and the FHIR flame design are registered trademarks of Health Level Seven International. Their use does not constitute endorsement by HL7.